Literature DB >> 19306395

Developmental and reproductive toxicity studies on artemisone.

G Schmuck1, A-M Klaus, F Krötlinger, F W Langewische.   

Abstract

BACKGROUND: In order to justify clinical studies in women of child-bearing age with artemisone, a new artimisinin derivative, studies to assess fertility and early embryonic development in rats, developmental toxicity in rats and rabbits, and peri-post natal development in rats were performed. METHODS AND
RESULTS: In the study on fertility and early embryonic development (dose levels 0-5-20-80 mg/kg bw/day), doses inducing clinical and organ toxicity were used. Only in severe toxicity conditions, a reduction of the number of estruses, a prolonged time to insemination, decreased numbers of corpora lutea, implantation sites, and viable fetuses were found. Two developmental toxicity studies were performed in rats (dose levels 0-1-2 mg/kg bw/day) and rabbits (dose levels 0-2.5-5.0-7.5 mg/kg bw/day). It was shown that rats were about 5 times more sensitive than rabbits. In rats, artemisone induced total litter loss (late resorptions) at 2 mg/kg body weight and above with an increased incidence of a common vascular variation and retarded ossification at this dose. In rabbits, maternal toxicity, abortion and a slightly increased incidence of cardiac ventricular septal defects was observed at 7.5 mg/kg body weight. In a pre- and postnatal developmental toxicity study in rats (dose levels 0-1-2-4 mg/kg bw/day), 4 mg/kg body weight artemisone induced clinical symptoms and affected postnatal survival, body weight gain in the F1 pups, and motor activity.
CONCLUSIONS: In summary, artemisone was shown to be embryo- and fetotoxic and induced cardiac ventricular septal defects and retarded ossification in dosages where total litter loss and abortions were observed. However, no effect on reproductive and developmental parameters below severe toxic dosages could be observed. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19306395     DOI: 10.1002/bdrb.20192

Source DB:  PubMed          Journal:  Birth Defects Res B Dev Reprod Toxicol        ISSN: 1542-9733


  8 in total

Review 1.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

2.  Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model.

Authors:  Ildiko R Dunay; Wing Chi Chan; Richard K Haynes; L David Sibley
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

3.  Treatment of murine cerebral malaria by artemisone in combination with conventional antimalarial drugs: antiplasmodial effects and immune responses.

Authors:  W Armand Guiguemde; Nicholas H Hunt; Jintao Guo; Annael Marciano; Richard K Haynes; Julie Clark; R Kiplin Guy; Jacob Golenser
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

4.  Glucocorticosteroids in nano-sterically stabilized liposomes are efficacious for elimination of the acute symptoms of experimental cerebral malaria.

Authors:  Judith H Waknine-Grinberg; Simcha Even-Chen; Jasmine Avichzer; Keren Turjeman; Annael Bentura-Marciano; Richard K Haynes; Lola Weiss; Nahum Allon; Haim Ovadia; Jacob Golenser; Yechezkel Barenholz
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

5.  Controlled release of artemisone for the treatment of experimental cerebral malaria.

Authors:  Jacob Golenser; Viola Buchholz; Amir Bagheri; Abed Nasereddin; Ron Dzikowski; Jintao Guo; Nicholas H Hunt; Sara Eyal; Natalia Vakruk; Andreas Greiner
Journal:  Parasit Vectors       Date:  2017-03-01       Impact factor: 3.876

6.  Treatment of Experimental Cerebral Malaria by Slow Release of Artemisone From Injectable Pasty Formulation.

Authors:  Jacob Golenser; Nadeen Salaymeh; Abd Alroof Higazi; Mohammed Alyan; Mahran Daif; Ron Dzikowski; Abraham J Domb
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

Review 7.  Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women.

Authors:  Qigui Li; Peter J Weina
Journal:  Molecules       Date:  2009-12-25       Impact factor: 4.411

8.  Unlocking Nanocarriers for the Programmed Release of Antimalarial Drugs.

Authors:  Amir Reza Bagheri; Seema Agarwal; Jacob Golenser; Andreas Greiner
Journal:  Glob Chall       Date:  2017-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.